Our lab studies mechanisms of lung ischemia-reperfusion injury (IRI), diagnosis of IRI, and identifying therapeutic strategies to prevent IRI after lung transplantation. Our studies explore the role of innate immune cells, alveolar epithelial cells, endothelial cells, and pro- or anti-inflammatory mediators. Ongoing research projects are summarized here.
We are studying the role of ATP released by pannexin-1 channels on endothelial cells in vascular inflammation and neutrophil infiltration after lung transplantation. More >>
We are evaluating novel, cell-specific molecular imaging probes for non-invasive PET or SPECT imaging to provide early detection of lung IRI. More >>
We are using EVLP as a platform for delivery of pharmacologic therapies to recondition DCD (donation after circulatory death) lungs for successful transplantation. More >>
We are devoloping a novel in vivo lung perfusion (IVLP) method as a targeted therapy to treat severe acute respiratory distress syndrome (ARDS). More >>
We are studying methods to prevent lung IRI by protecting the endothelial barrier via strengthening the vascular S1P gradient. More >>
We are studying the role of IL-10, IL-4, M2 macrophages, and Treg cells in the resolution of lung IRI as well as ways to augment resolution of injury in transplanted lungs. More >>